Osteoarthritis joint pain and function
Multiple RCTs demonstrate UC-II® 40 mg/day significantly reduces joint pain, stiffness, and improves physical function in knee osteoarthritis patients — with effects comparable to or exceeding glucosamine plus chondroitin at 1,500 mg + 1,200 mg/day. The mechanism is entirely different: UC-II® works immunologically, not structurally.
Superior efficacy vs. glucosamine and chondroitin
A head-to-head RCT directly compared UC-II® 40 mg/day vs. glucosamine (1,500 mg) + chondroitin (1,200 mg) combination in 52 OA patients over 90 days. UC-II® produced significantly greater improvements in overall joint pain, rest pain, joint function, and quality of life — establishing UC-II® as the more effective joint supplement at 1/37th the dose.
Exercise-induced joint discomfort in healthy adults
UC-II® 40 mg/day significantly reduces exercise-induced knee pain and improves joint comfort during and after physical activity in active adults without diagnosed OA. The oral tolerance mechanism provides protective immunological modulation before articular damage progresses.
Knee flexion range of motion
Clinical studies show UC-II® supplementation significantly improves knee flexion range of motion — the ability to bend the knee through its full arc. This functional improvement reflects reduced joint inflammation and improved synovial fluid viscosity, translating to better mobility and reduced activity limitations.
Oral tolerization via Peyer's patches
Native (undenatured) type II collagen, when ingested whole, is recognized by Peyer's patches in the small intestinal wall — immune sensing organs that orchestrate oral tolerance. Regulatory T-cells (Tregs) generated in this process migrate to joint tissue and suppress local autoimmune attack on cartilage collagen, reducing inflammation through immunological modulation rather than pharmacological inhibition.
TGF-β and IL-10 anti-inflammatory cytokine production
Oral tolerance induction via UC-II® drives Treg cells to produce TGF-β (transforming growth factor-beta) and IL-10 (interleukin-10) — potent anti-inflammatory cytokines that suppress Th1 and Th17 joint inflammation locally. This bystander suppression effect specifically targets cartilage-attacking immune responses.
Chondrocyte protection and cartilage matrix preservation
By suppressing the immune-mediated destruction of articular cartilage, UC-II® protects chondrocytes from cytokine-induced apoptosis and preserves the proteoglycan and collagen matrix of cartilage tissue. Over time, this immunological protection allows cartilage maintenance and potentially partial repair.
Randomized, double-blind, placebo-controlled trial directly comparing UC-II® (40 mg/day) vs. glucosamine (1,500 mg) + chondroitin sulfate (1,200 mg) vs. placebo in 52 knee OA patients for 90 days.
52 adults with knee OA. 90-day three-arm trial.
UC-II® produced significantly greater improvements in overall pain (WOMAC: -33% vs -14% G+C), rest pain, joint function, and quality of life. UC-II® outperformed G+C at 1/37th the daily dose. Both active groups outperformed placebo. Landmark head-to-head trial establishing UC-II® superiority.
Randomized, double-blind, placebo-controlled trial of UC-II® (40 mg/day) vs. placebo in 55 healthy adults experiencing exercise-induced knee discomfort for 120 days.
55 healthy active adults with exercise-induced knee discomfort. 120-day intervention.
UC-II® significantly reduced exercise-induced knee pain scores, improved knee extension range of motion after exercise, and improved overall joint comfort vs. placebo. Supports UC-II® for healthy active population joint maintenance before OA diagnosis.
Extended follow-up of UC-II® clinical trials examining safety and sustained efficacy over 180 days of continuous use.
Knee OA patients continuing from initial 90-day RCT. 180-day total.
Continued improvements in joint pain and function at 180 days, with no attenuation of effect. No serious adverse events. Safety labs (CBC, liver function, kidney function) unchanged from baseline. Confirms long-term safety and sustained efficacy.